Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse, der evaluerer BFB759 ved moderat til svær hidradenitis suppurativa (COMPASS 2-HS)

12. oktober 2026 opdateret af: Bluefin Biomedicine, Inc.

En fase 2-doseringsundersøgelse, randomiseret, dobbeltblind, placebo-kontrolleret undersøgelse for at evaluere effektiviteten og sikkerheden af BFB759 hos patienter med moderat til svær hidradenitis suppurativa

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

210

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Burgas, Bulgarien
        • Medical Center Medconsult Burgas EOOD
      • Lovech, Bulgarien
        • Medical Center Medconsult Pleven-Lovech Branch
      • Pleven, Bulgarien
        • Medical Center Medconsult Pleven OOD
      • Plovdiv, Bulgarien
        • Medical Center Etika Ambulatory For Specialized Outpatient Medical Care OOD
      • Rousse, Bulgarien
        • Medical Center Rusemed
    • Alberta
      • Edmonton, Alberta, Canada, AB T5J 3S9
        • Laser Rejuvenation Clinics Edmonton D.T. Inc.
    • Ontario
      • Richmond Hill, Ontario, Canada, L4B 1L1
        • York Dermatology Clinical and Research Centre
      • Toronto, Ontario, Canada, M2N 3A6
        • North York Research Inc.
    • Quebec
      • Québec, Quebec, Canada, QC G1W 4R4
        • Centre de Recherche Saint-Louis (Quebec)
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85008
        • Saguaro Dermatology
    • California
      • Encino, California, Forenede Stater, 91436
        • Encino Research Center
      • Huntington Beach, California, Forenede Stater, 92647
        • Marvel Clinical Research LLC
      • Santa Monica, California, Forenede Stater, 90404
        • Clinical Science Institute
    • Florida
      • Boca Raton, Florida, Forenede Stater, 33021
        • Skin Care Research
      • Fort Lauderdale, Florida, Forenede Stater, 33308
        • Center for Skin Science and Innovation
      • Margate, Florida, Forenede Stater, 33063
        • Gsi Clinical Research
      • North Miami Beach, Florida, Forenede Stater, 33126
        • Ziaderm Research LLC
      • Tampa, Florida, Forenede Stater, 33607
        • Clinical Trials Management, LLC
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30329
        • DelRicht Research
      • Douglasville, Georgia, Forenede Stater, 30135
        • Southeast Research Specialist LLC
    • Indiana
      • Plainfield, Indiana, Forenede Stater, 46168
        • The Indiana Clinical Trials Center, PC
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40241
        • DS Research of Kentucky
    • Louisiana
      • Mandeville, Louisiana, Forenede Stater, 70448
        • Martha Stewart
      • Metairie, Louisiana, Forenede Stater, 70006
        • Clinical Trials Management, LLC
      • New Orleans, Louisiana, Forenede Stater, 70115
        • DelRicht Research
    • Michigan
      • Auburn Hills, Michigan, Forenede Stater, 48326
        • Oakland Hills Dermatology
      • Northville, Michigan, Forenede Stater, 48167
        • MI Skin Innovations
    • Missouri
      • Wildwood, Missouri, Forenede Stater, 63040
        • DelRicht Research
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89145
        • JDR Dermatology Research LLC
      • Reno, Nevada, Forenede Stater, 89509
        • Skin Cancer and Dermatology Institute
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Schweiger Dermatology, PC
    • New York
      • The Bronx, New York, Forenede Stater, 10455
        • Equity Medical LLC
    • Ohio
      • Boardman, Ohio, Forenede Stater, 44512
        • Optima Research - Boardman
      • Canton, Ohio, Forenede Stater, 44718
        • Apex Clinical Research Center, LLC
      • Mayfield Heights, Ohio, Forenede Stater, 44124
        • Apex Clinical Research Center, LLC
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • UPMC Department of Dermatology
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Medical Univ of SC Department of Dermatology
      • Mt. Pleasant, South Carolina, Forenede Stater, 29464
        • DelRicht Research
    • Tennessee
      • Smyrna, Tennessee, Forenede Stater, 37167
        • DelRicht Research
    • Texas
      • Dallas, Texas, Forenede Stater, 75230
        • Dermatology Treatment & Research Center
      • Frisco, Texas, Forenede Stater, 75033
        • VAST Clinical Research LLC
      • Prosper, Texas, Forenede Stater, 75078
        • DelRicht Research
      • Southlake, Texas, Forenede Stater, 76092
        • Stryde Research-Epiphany Dermatology
    • Washington
      • Spokane, Washington, Forenede Stater, 99202
        • Dermatology Specialists of Spokane
      • Bialystok, Polen
        • NZOZ Specjal. Osrodek Dermatologiczny DERMAL
      • Lublin, Polen
        • Luxderm Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
      • Wroclaw, Polen
        • Melita Medical
      • Wroclaw, Polen
        • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
      • Wroclaw, Polen
        • Wojewódzki Szpital Specjalistyczny we Wrocławi,Oddział Dermatologiczny
      • Granada, Spanien
        • Hospital Universitario Virgen De Las Nieves
      • Granollers, Spanien
        • Hospital Asil de Granollers
      • Las Palmas de Gran Canaria, Spanien
        • Hospital Universitario de Gran Canaria Doctor Negrin
      • Madrid, Spanien
        • Hospital Gregorio Maranon
      • Pontevedra, Spanien
        • Complejo Hospitalario Universitario de Pontevedra
      • Valencia, Spanien
        • Hospital de Manises
      • Ostrava, Tjekkiet
        • CCR Ostrava s.r.o.
      • Pardubice, Tjekkiet
        • Pratia Pardubice a.s.
      • Prague, Tjekkiet
        • Sanatorium of Professor Arenbergera
      • Bochum, Tyskland
        • St. Josef-Hospital Bochum
      • Frankfurt, Tyskland
        • Universitatsklinikum Frankfurt Klinik fur Dermatologie, Venerologie und Allergologie
      • Heidelberg, Tyskland
        • University Clinic Dermatology Heidelberg
      • Leipzig, Tyskland
        • University Hospital, Leipzig
      • Lübeck, Tyskland
        • University of Luebeck
      • Munich, Tyskland
        • Klinik und Poliklinik fur Dermatologie und Allergologie

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year.
  • Have moderate to severe disease not well controlled by systemic antibiotic treatment.
  • Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.

Exclusion Criteria:

  • Have certain infections or other immune conditions.
  • Recently used medications that could interfere with the study.
  • Are pregnant or breastfeeding.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Active - high dose

BFB759 loading dose followed by BFB759 maintenance high dose every 2 weeks (Q2W) through Week 14 (inclusive), which is followed by placebo Q2W at Weeks 16 through 30 (inclusive).

BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including hidradenitis suppurativa.

Eksperimentel: Active - low dose

BFB759 loading dose followed by BFB759 maintenance mid-dose Q2W through Week 14 (inclusive).

BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including hidradenitis suppurativa.

Placebo komparator: Placebo

Placebo Q2W for 14 weeks. At Week 16, participants in Placebo group who are still enrolled in the study and receiving treatment will be re-randomized (1:1) into 2 groups (Cross 1 and Cross 2) to receive BFB759

  • Cross 1 will receive BFB759 loading dose followed by BFB759 maintenance low-dose Q2W through Week 30 (inclusive).
  • Cross 2 will receive BFB759 loading dose followed by BFB759 maintenance mid-dose Q2W through Week 30 (inclusive).

Placebo for BFB759

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Efficacy of BFB759 in HS
Tidsramme: Baseline to Week 16 and baseline to Week 32

To evaluate the efficacy of BFB759 in adult male and female participants with HS as measured by the change in the number of abscesses and inflammatory nodules (AN count).

Baseline to Week 16 and baseline to Week 32

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Evaluate the clinical activity of BFB759 using HiSCR50
Tidsramme: Baseline to Week 16 and baseline to Week 32

The HiSCR50 is defined as at least a 50% reduction in inflammatory lesion count [the sum of Abscesses and Inflammatory Nodules (AN)] and no increase in abscess count and no increase in draining fistula count relative to baseline. The threshold of 50% reduction in AN count is the defined level that is clinically appropriate and meaningful to the patient regarding improvement in quality of life and pain level.

Baseline to Week 16 and baseline to Week 32
Evaluate the safety/tolerability of BFB759
Tidsramme: routinely over 21 months (about 22 visits during the course of study)

Record how well participants tolerate the treatment over time by recording the incidence and severity of treatment-emergent adverse events (as described by CTCAE Version 5.0)

routinely over 21 months (about 22 visits during the course of study)
To evaluate the clinical activity of BFB759 using the International Hidradenitis Suppurativa Severity Score System (IHS4)
Tidsramme: Baseline to Week 16 and baseline to Week 32

The IHS4 is a validated tool to dynamically assess HS severity that can be used both in real-life and the clinical trials setting (Zouboulis, 2017). It is calculated by counting nodules, abscesses and dTs/sinus tracts, and calculating a total score. IHS4 = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of dTs multiplied by 4].

Baseline to Week 16 and baseline to Week 32
To evaluate the clinical activity of BFB759 using the Skin Pain Numerical Rating Scale (NRS)
Tidsramme: Baseline to Week 16 and baseline to Week 32

The Skin Pain NRS is a single self-reported item designed to measure skin pain severity over the previous 24 hours. The following question is asked, and the response is marked on an 11 point scale where 0 equals no pain and 10 equals the worst pain imaginable.

Baseline to Week 16 and baseline to Week 32
To evaluate the clinical activity of BFB759 using the Hidradenitis Suppurativa-Investigator Global Assessment (HS-IGA)
Tidsramme: Baseline to Week 16 and baseline to Week 32

The HS IGA is a HS-specific global assessment. It is a 6 point ordinal scale based on objective lesion counts (Garg, 2022). Scores are calculated by the sum of abscesses, nodules (inflammatory or noninflammatory) and tunnels (draining or nondraining) in either the upper body regions or the lower body regions, whichever is greater. Scores are assigned as follows: 0 (0 1 lesions), 1 (2 5 lesions), 2 (6 10 lesions), 3 (11 15 lesions), 4 (16 20 lesions), and 5 (>20 lesions).

Baseline to Week 16 and baseline to Week 32

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. november 2025

Primær færdiggørelse (Anslået)

1. august 2027

Studieafslutning (Anslået)

1. august 2027

Datoer for studieregistrering

Først indsendt

13. november 2025

Først indsendt, der opfyldte QC-kriterier

12. december 2025

Først opslået (Faktiske)

17. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

14. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CL-BFB759-003
  • COMPASS 2-HS (Anden identifikator: Sponsor)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .